Ndoli Minega Jules
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ndoli Minega Jules has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Djibril Mbarushimana
University Teaching Hospital of Butare, P.O. Box 254, Hospital Avenue, Mamba Ngoma, Huye, Rwanda, 250 788575656
4 shared publications - Felicite Mukamana
University Teaching Hospital of Butare, P.O. Box 254, Hospital Avenue, Mamba Ngoma, Huye, Rwanda, 250 788575656
4 shared publications - Gatera Jean Damascene
University Teaching Hospital of Butare, P.O. Box 254, Hospital Avenue, Mamba Ngoma, Huye, Rwanda, 250 788575656
4 shared publications - Issa Bagirinshuti
University Teaching Hospital of Butare, P.O. Box 254, Hospital Avenue, Mamba Ngoma, Huye, Rwanda, 250 788575656
4 shared publications - Ngarambe Christian
University Teaching Hospital of Butare, P.O. Box 254, Hospital Avenue, Mamba Ngoma, Huye, Rwanda, 250 788575656
4 shared publications - Theogene Twagirumugabe
University Teaching Hospital of Butare, P.O. Box 254, Hospital Avenue, Mamba Ngoma, Huye, Rwanda, 250 788575656
4 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Eliminating Patient Queues for Payment via Asynchronous Mobile Money Integration: Architecture and an Eight-Month Performance Evaluation at a Rwandan Tertiary Hospital (Preprint)
BACKGROUND Patient payment queuing at hospital cashier desks is a persistent operational challenge in resource-limited healthcare settings. In October 2025, the University Teaching Hospital of Butare (CHUB), a public tertiary referral centre in Rwanda, integrated an asynchronous Mobile Money payment module with its OpenClinic GA hospital management information system (HMIS) through the Irembo payment gateway, as an unfunded quality improvement initiative. OBJECTIVE To describe the integration architecture and quantify its impact on patient payment cycle time, channel adoption, and transaction reliability over eight months of routine operation. METHODS The architecture is described from direct analysis of the deployed production source code. Performance was evaluated by retrospective analysis of all closed invoices for prepaid services (laboratory, imaging, pharmacy) from 1 October 2025 to 31 May 2026. Payment cycle time was defined as the interval from bill creation to payment confirmation; transactions exceeding 24 hours were excluded. RESULTS The integration implements a fully asynchronous, non-blocking model with dual trigger pathways (patient-initiated SMS and staff-initiated HMIS form) and a four-step Irembo API workflow. Across 146,203 invoiced episodes, Mobile Money adoption grew from 3.8% to 20.9%. Among 131,037 within-24-hour transactions, median payment cycle time was 5 minutes for Mobile Money versus 72 minutes for cash, a 93.1% reduction. The system processed 44,216 transactions with a 97.9% success rate; all failure causes were identified and resolved. Insurer paper-documentation requirements were the principal structural ceiling on adoption. CONCLUSIONS Asynchronous mobile money integration delivered large, sustained reductions in patient payment waiting time and provides a reproducible reference model for sub-Saharan African hospitals.
- 21 July 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEliminating Patient Queues for Payment via Asynchronous Mobile Money Integration: Architecture and an Eight-Month Performance Evaluation at a Rwandan Tertiary Hospital (Preprint)
BACKGROUND Patient payment queuing at hospital cashier desks is a persistent operational challenge in resource-limited healthcare settings. In October 2025, the University Teaching Hospital of Butare (CHUB), a public tertiary referral centre in Rwanda, integrated an asynchronous Mobile Money payment module with its OpenClinic GA hospital management information system (HMIS) through the Irembo payment gateway, as an unfunded quality improvement initiative. OBJECTIVE To describe the integration architecture and quantify its impact on patient payment cycle time, channel adoption, and transaction reliability over eight months of routine operation. METHODS The architecture is described from direct analysis of the deployed production source code. Performance was evaluated by retrospective analysis of all closed invoices for prepaid services (laboratory, imaging, pharmacy) from 1 October 2025 to 31 May 2026. Payment cycle time was defined as the interval from bill creation to payment confirmation; transactions exceeding 24 hours were excluded. RESULTS The integration implements a fully asynchronous, non-blocking model with dual trigger pathways (patient-initiated SMS and staff-initiated HMIS form) and a four-step Irembo API workflow. Across 146,203 invoiced episodes, Mobile Money adoption grew from 3.8% to 20.9%. Among 131,037 within-24-hour transactions, median payment cycle time was 5 minutes for Mobile Money versus 72 minutes for cash, a 93.1% reduction. The system processed 44,216 transactions with a 97.9% success rate; all failure causes were identified and resolved. Insurer paper-documentation requirements were the principal structural ceiling on adoption. CONCLUSIONS Asynchronous mobile money integration delivered large, sustained reductions in patient payment waiting time and provides a reproducible reference model for sub-Saharan African hospitals.
- Open Access
- 24 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Digital Integration of CLSI and EUCAST Guidelines in Antimicrobial Susceptibility Testing Reporting: A Pre and Post Implementation Study at a Rwandan Tertiary Hospital (Preprint)
BACKGROUND Antimicrobial resistance (AMR) is a global health emergency, disproportionately impacting sub-Saharan Africa where fragmented laboratory information systems (LIS) and inconsistent antimicrobial susceptibility testing (AST) practices limit both clinical decision-making and surveillance capacity. At the University Teaching Hospital of Butare (CHUB) in Rwanda, a baseline Laboratory Assessment of Antibiotic Resistance Testing Capacity (LAARC) identified systemic gaps, including 0% AST panel standardization, 17% cumulative antibiogram generation capacity, and no enforcement of testing quality rules. A standards-based digital infrastructure integrating CLSI- and EUCAST-compliant AST panels into OpenClinic GA with bidirectional WHONet export was implemented in 2024. The implementing study expressly deferred quantitative key performance indicator (KPI) evaluation to allow sufficient post-implementation observation time. OBJECTIVE To quantify the impact of the implemented infrastructure on five KPI domains: (1) AST data capture volume and specimen throughput; (2) data standardization and ease of analysis; (3) laboratory turnaround time (TAT); (4) testing quality, including detection and resolution of specimen-antibiotic incompatibilities, method violations, and intrinsic resistance violations; and (5) antimicrobial resistance (AMR) profiles, including appropriate use of screener discs. METHODS A retrospective pre-post study compared Q1 2024 (pre-implementation; n=505 culture-positive specimens, legacy LIS export) with Q1 2026 (post-implementation; n=3,669 specimens, WHONet-format export) at CHUB. Outcomes included specimen throughput, nomenclature and data structure standardization, TAT (specimen receipt to results release, days), testing quality flags (Nitrofurantoin/Nalidixic acid on non-urine specimens; vancomycin by disc diffusion on staphylococci; ampicillin on intrinsically resistant Enterobacteriaceae), screener disc utilization (Pefloxacin, Cefoxitin), and resistance rates for key pathogens against CLSI 2024 breakpoints. RESULTS Specimen throughput increased 7.3-fold (+626%). Unique organism names decreased from 76 to 39 (-49%), with 11 non-standard spellings of Escherichia coli alone pre-implementation reduced to one WHO-standard entry. All 7,465 post-implementation records carried CLSI 2024 annotations versus 0% pre-implementation. Critical data-analysis fields, age categories, department, TAT timestamps, WHONET antibiotic codes, absent pre-implementation were fully present post-implementation. Pre-implementation errors included: 6 instances of Nitrofurantoin or Nalidixic acid on non-urine specimens, 4 instances of ampicillin on intrinsically resistant Enterobacteriaceae (including 1 spurious susceptible result), and 44 vancomycin results by disc diffusion on staphylococci and streptococci (16 on Staphylococcus aureus), an unreliable method per CLSI. All resolved to zero post-implementation. Screener disc use was transformed: Pefloxacin (fluoroquinolone surrogate for Enterobacteriaceae) was absent pre-implementation and introduced in 95 tests post-implementation; Cefoxitin (MRSA surrogate) was used without a systematic inferential framework pre-implementation (n=81, no inferential display) and formalised under the screener protocol post-implementation (n=33, MRSA rate 24.2%). Median TAT from specimen receipt to results release was 2.80 days (IQR 2.03-3.77). Among key pathogens, Escherichia coli ciprofloxacin resistance was 54.2% and ceftriaxone resistance 42.2%, while carbapenem susceptibility was preserved (imipenem resistance 1.5%). CONCLUSIONS Implementation of a CLSI/EUCAST-compliant digital AST and surveillance infrastructure at CHUB produced measurable, clinically meaningful improvements across all five KPI domains, yielding CHUB's first institution-wide cumulative antibiogram in GLASS-compatible WHONet format. These results fulfill the deferred quantitative evaluation and provide a replicable evidence base for tertiary institutions across sub-Saharan Africa. INTERNATIONAL REGISTERED REPORT RR2-10.2196/82727
- 24 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDigital Integration of CLSI and EUCAST Guidelines in Antimicrobial Susceptibility Testing Reporting: A Pre and Post Implementation Study at a Rwandan Tertiary Hospital (Preprint)
BACKGROUND Antimicrobial resistance (AMR) is a global health emergency, disproportionately impacting sub-Saharan Africa where fragmented laboratory information systems (LIS) and inconsistent antimicrobial susceptibility testing (AST) practices limit both clinical decision-making and surveillance capacity. At the University Teaching Hospital of Butare (CHUB) in Rwanda, a baseline Laboratory Assessment of Antibiotic Resistance Testing Capacity (LAARC) identified systemic gaps, including 0% AST panel standardization, 17% cumulative antibiogram generation capacity, and no enforcement of testing quality rules. A standards-based digital infrastructure integrating CLSI- and EUCAST-compliant AST panels into OpenClinic GA with bidirectional WHONet export was implemented in 2024. The implementing study expressly deferred quantitative key performance indicator (KPI) evaluation to allow sufficient post-implementation observation time. OBJECTIVE To quantify the impact of the implemented infrastructure on five KPI domains: (1) AST data capture volume and specimen throughput; (2) data standardization and ease of analysis; (3) laboratory turnaround time (TAT); (4) testing quality, including detection and resolution of specimen-antibiotic incompatibilities, method violations, and intrinsic resistance violations; and (5) antimicrobial resistance (AMR) profiles, including appropriate use of screener discs. METHODS A retrospective pre-post study compared Q1 2024 (pre-implementation; n=505 culture-positive specimens, legacy LIS export) with Q1 2026 (post-implementation; n=3,669 specimens, WHONet-format export) at CHUB. Outcomes included specimen throughput, nomenclature and data structure standardization, TAT (specimen receipt to results release, days), testing quality flags (Nitrofurantoin/Nalidixic acid on non-urine specimens; vancomycin by disc diffusion on staphylococci; ampicillin on intrinsically resistant Enterobacteriaceae), screener disc utilization (Pefloxacin, Cefoxitin), and resistance rates for key pathogens against CLSI 2024 breakpoints. RESULTS Specimen throughput increased 7.3-fold (+626%). Unique organism names decreased from 76 to 39 (-49%), with 11 non-standard spellings of Escherichia coli alone pre-implementation reduced to one WHO-standard entry. All 7,465 post-implementation records carried CLSI 2024 annotations versus 0% pre-implementation. Critical data-analysis fields, age categories, department, TAT timestamps, WHONET antibiotic codes, absent pre-implementation were fully present post-implementation. Pre-implementation errors included: 6 instances of Nitrofurantoin or Nalidixic acid on non-urine specimens, 4 instances of ampicillin on intrinsically resistant Enterobacteriaceae (including 1 spurious susceptible result), and 44 vancomycin results by disc diffusion on staphylococci and streptococci (16 on Staphylococcus aureus), an unreliable method per CLSI. All resolved to zero post-implementation. Screener disc use was transformed: Pefloxacin (fluoroquinolone surrogate for Enterobacteriaceae) was absent pre-implementation and introduced in 95 tests post-implementation; Cefoxitin (MRSA surrogate) was used without a systematic inferential framework pre-implementation (n=81, no inferential display) and formalised under the screener protocol post-implementation (n=33, MRSA rate 24.2%). Median TAT from specimen receipt to results release was 2.80 days (IQR 2.03-3.77). Among key pathogens, Escherichia coli ciprofloxacin resistance was 54.2% and ceftriaxone resistance 42.2%, while carbapenem susceptibility was preserved (imipenem resistance 1.5%). CONCLUSIONS Implementation of a CLSI/EUCAST-compliant digital AST and surveillance infrastructure at CHUB produced measurable, clinically meaningful improvements across all five KPI domains, yielding CHUB's first institution-wide cumulative antibiogram in GLASS-compatible WHONet format. These results fulfill the deferred quantitative evaluation and provide a replicable evidence base for tertiary institutions across sub-Saharan Africa. INTERNATIONAL REGISTERED REPORT RR2-10.2196/82727
- Top Cited PapersOpen Access
The Global Landscape of Plasmodium falciparum Drug Resistance Markers, 2005–2025: A Systematic Review and Meta-Analysis
Malaria remains a global health threat, with Plasmodium falciparum causing most deaths, especially in sub-Saharan Africa. Although artemisinin-based therapies reduce the burden, drug-resistant parasites threaten control efforts. Mapping the distribution and evolution of molecular resistance markers is vital for evidence-based strategies. This systematic review mapped the global distribution, pooled prevalence, and temporal trends of key P. falciparum antimalarial resistance markers. Following the PRISMA methodology (PROSPERO: CRD4202511098991), databases (PubMed, Web of Science, Scopus, and Google Scholar) and gray sources were searched (July 2005–July 2025). Data were extracted in Rayyan, assessed via the JBI prevalence tool, and analyzed using Python v3.13 for WHO regional distribution, temporal trends, and treatment outcome trends. Of the 1972 records, 261 studies from 64 countries qualified for inclusion in this review. The pooled prevalence was highest for pfdhfr (85.7%), followed by pfcrt (78.0%), pfdhps (73.7%), pfmdr1 (60.5%), and pfk13 (45.0%). High heterogeneity (I2 > 95%) and rising pfk13 since 2012 highlight emerging artemisinin resistance, while persistent pfdhfr/pfdhps mutations show that ongoing sulfadoxine–pyrimethamine (SP) pressure on P. falciparum drug resistance, decreased parasite clearance, and treatment failure remain widespread and evolving in Africa. Integrating molecular surveillance into national malaria programs is essential to guide treatment modalities and support progress toward malaria elimination.
Top Cited PapersOpen AccessThe Global Landscape of Plasmodium falciparum Drug Resistance Markers, 2005–2025: A Systematic Review and Meta-Analysis
Malaria remains a global health threat, with Plasmodium falciparum causing most deaths, especially in sub-Saharan Africa. Although artemisinin-based therapies reduce the burden, drug-resistant parasites threaten control efforts. Mapping the distribution and evolution of molecular resistance markers is vital for evidence-based strategies. This systematic review mapped the global distribution, pooled prevalence, and temporal trends of key P. falciparum antimalarial resistance markers. Following the PRISMA methodology (PROSPERO: CRD4202511098991), databases (PubMed, Web of Science, Scopus, and Google Scholar) and gray sources were searched (July 2005–July 2025). Data were extracted in Rayyan, assessed via the JBI prevalence tool, and analyzed using Python v3.13 for WHO regional distribution, temporal trends, and treatment outcome trends. Of the 1972 records, 261 studies from 64 countries qualified for inclusion in this review. The pooled prevalence was highest for pfdhfr (85.7%), followed by pfcrt (78.0%), pfdhps (73.7%), pfmdr1 (60.5%), and pfk13 (45.0%). High heterogeneity (I2 > 95%) and rising pfk13 since 2012 highlight emerging artemisinin resistance, while persistent pfdhfr/pfdhps mutations show that ongoing sulfadoxine–pyrimethamine (SP) pressure on P. falciparum drug resistance, decreased parasite clearance, and treatment failure remain widespread and evolving in Africa. Integrating molecular surveillance into national malaria programs is essential to guide treatment modalities and support progress toward malaria elimination.
- Open Access
- 21 January 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e82727
Digital Infrastructure for Antimicrobial Susceptibility Testing and Surveillance: A CLSI and EUCAST-Based Model for Resource-Limited Settings
Background: Antimicrobial resistance (AMR) poses a significant global health threat, requiring effective antimicrobial susceptibility testing (AST) and surveillance systems. At the University Teaching Hospital of Butare (CHUB) in Rwanda, a baseline Laboratory Assessment of Antibiotic Resistance Testing Capacity (LAARC) identified critical gaps in the Laboratory Information System (LIS), including low capture rates for culture observation (60%) and AST data (25%), no standardization of AST panels (0%), and limited cumulative antibiogram generation (17%). Existing AMR surveillance platforms, such as the Information System for Monitoring Antimicrobial Resistance by the World Health Organization (WHO) Collaborating Center for Surveillance of Resistance to Antimicrobial Agents (WHONET), and the District Health Information System, operate as standalone systems separate from clinical workflows, which limits their real-time clinical utility. Objective: This study aimed to develop an enhanced, web-based LIS integrated within routine clinical care to improve AST reliability, enable real-time AMR surveillance at CHUB, and provide a scalable model for subnational and national surveillance networks in resource-limited settings, supporting antimicrobial stewardship. Methods: We developed an enhanced LIS using the OpenClinic GA, the current open-source hospital information system at CHUB, integrating Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines, and leveraging metadata from the AMR for R package, WHONET resources, and EUCAST Expert Rules. An agile development approach was used, incorporating a custom database schema, Java-based application programming interfaces (APIs), and web-based user interfaces. The system was designed to support minimum inhibitory concentration (MIC) and disk diffusion (DD) methods, automate result interpretation with color-coded outputs, WHO Access, Watch, Reserve (AWaRe)–based cascade reporting, and enable data export to WHONET for global surveillance. Results: The enhanced LIS improved AST data capture and standardization, providing reliable, automated result interpretation and real-time AMR surveillance capabilities. The system’s web-based architecture enables scalability through centralized deployment, allowing multiple facilities simultaneous access. Unlike standalone surveillance tools, the enhanced LIS integrates AST within electronic medical records, maintaining clinical information continuity from specimen registration through result reporting. The system supports immediate clinical decision through AWaRe–based cascade reporting, and automated resistance phenotype detection, followed by standardized WHONET-compatible exports for public health surveillance. Conclusions: This scalable, LIS model demonstrates the feasibility of implementing standards-based AMR informatics in resource-limited settings. By embedding surveillance within clinical workflows rather than treating it as a separate downstream activity, the system maximizes data quality and clinical relevance while minimizing staff burden. The centralized web-based architecture provides inherent scalability from facility to national levels, eliminating data fragmentation and ensuring metadata consistency across networks. Long-term sustainability requires continuous user training, designated personnel for metadata maintenance, local IT capacity building, and funding mechanisms beyond donor dependency. This model provides a practical roadmap for national digital stewardship programs, supporting both immediate patient care and long-term public health surveillance goals.
- 21 January 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e82727
Open AccessDigital Infrastructure for Antimicrobial Susceptibility Testing and Surveillance: A CLSI and EUCAST-Based Model for Resource-Limited Settings
Background: Antimicrobial resistance (AMR) poses a significant global health threat, requiring effective antimicrobial susceptibility testing (AST) and surveillance systems. At the University Teaching Hospital of Butare (CHUB) in Rwanda, a baseline Laboratory Assessment of Antibiotic Resistance Testing Capacity (LAARC) identified critical gaps in the Laboratory Information System (LIS), including low capture rates for culture observation (60%) and AST data (25%), no standardization of AST panels (0%), and limited cumulative antibiogram generation (17%). Existing AMR surveillance platforms, such as the Information System for Monitoring Antimicrobial Resistance by the World Health Organization (WHO) Collaborating Center for Surveillance of Resistance to Antimicrobial Agents (WHONET), and the District Health Information System, operate as standalone systems separate from clinical workflows, which limits their real-time clinical utility. Objective: This study aimed to develop an enhanced, web-based LIS integrated within routine clinical care to improve AST reliability, enable real-time AMR surveillance at CHUB, and provide a scalable model for subnational and national surveillance networks in resource-limited settings, supporting antimicrobial stewardship. Methods: We developed an enhanced LIS using the OpenClinic GA, the current open-source hospital information system at CHUB, integrating Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines, and leveraging metadata from the AMR for R package, WHONET resources, and EUCAST Expert Rules. An agile development approach was used, incorporating a custom database schema, Java-based application programming interfaces (APIs), and web-based user interfaces. The system was designed to support minimum inhibitory concentration (MIC) and disk diffusion (DD) methods, automate result interpretation with color-coded outputs, WHO Access, Watch, Reserve (AWaRe)–based cascade reporting, and enable data export to WHONET for global surveillance. Results: The enhanced LIS improved AST data capture and standardization, providing reliable, automated result interpretation and real-time AMR surveillance capabilities. The system’s web-based architecture enables scalability through centralized deployment, allowing multiple facilities simultaneous access. Unlike standalone surveillance tools, the enhanced LIS integrates AST within electronic medical records, maintaining clinical information continuity from specimen registration through result reporting. The system supports immediate clinical decision through AWaRe–based cascade reporting, and automated resistance phenotype detection, followed by standardized WHONET-compatible exports for public health surveillance. Conclusions: This scalable, LIS model demonstrates the feasibility of implementing standards-based AMR informatics in resource-limited settings. By embedding surveillance within clinical workflows rather than treating it as a separate downstream activity, the system maximizes data quality and clinical relevance while minimizing staff burden. The centralized web-based architecture provides inherent scalability from facility to national levels, eliminating data fragmentation and ensuring metadata consistency across networks. Long-term sustainability requires continuous user training, designated personnel for metadata maintenance, local IT capacity building, and funding mechanisms beyond donor dependency. This model provides a practical roadmap for national digital stewardship programs, supporting both immediate patient care and long-term public health surveillance goals.
- Open Access
- 25 August 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (35)
Flavin-deficient erythrocytes offer protection against malaria parasites
Studies from the 1980s and 1990s conducted in Italy, where malaria was once endemic, hypothesized that individuals with erythrocytes deficient in flavin mononucleotide and flavin adenine dinucleotide (FAD)—collectively known as flavins—are partially protected against malaria. The condition was reported to be familial, consistent with a genetic element. This hypothesis, however, has never been tested. Using an erythrocyte FAD-dependent glutathione reductase activity assay, we identified individuals with flavin-deficient erythrocytes (FDE) in Ferrara, Italy (23% of 150 individuals screened), and in Huye, Rwanda (13% of 169 individuals). None of the individuals with FDE had a dietary riboflavin deficiency. Importantly, FDE from individuals in Ferrara, as well as erythrocytes depleted of flavins in vitro by riboflavin starvation, inhibited the intraerythrocytic proliferation of Plasmodium falciparum . We provide evidence that these erythrocytes are susceptible to oxidative stress, potentially explaining their inhibitory effect on parasite proliferation. Genetic analysis identified mutations in the FAD synthase gene of three individuals with FDE from Huye, consistent with a potential genetic basis.
- 25 August 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (35)
Open AccessFlavin-deficient erythrocytes offer protection against malaria parasites
Studies from the 1980s and 1990s conducted in Italy, where malaria was once endemic, hypothesized that individuals with erythrocytes deficient in flavin mononucleotide and flavin adenine dinucleotide (FAD)—collectively known as flavins—are partially protected against malaria. The condition was reported to be familial, consistent with a genetic element. This hypothesis, however, has never been tested. Using an erythrocyte FAD-dependent glutathione reductase activity assay, we identified individuals with flavin-deficient erythrocytes (FDE) in Ferrara, Italy (23% of 150 individuals screened), and in Huye, Rwanda (13% of 169 individuals). None of the individuals with FDE had a dietary riboflavin deficiency. Importantly, FDE from individuals in Ferrara, as well as erythrocytes depleted of flavins in vitro by riboflavin starvation, inhibited the intraerythrocytic proliferation of Plasmodium falciparum . We provide evidence that these erythrocytes are susceptible to oxidative stress, potentially explaining their inhibitory effect on parasite proliferation. Genetic analysis identified mutations in the FAD synthase gene of three individuals with FDE from Huye, consistent with a potential genetic basis.
- Open Access
- 1 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-8
Serological evidence of clade Ib Mpox transmission by sex workers and within household in South Kivu, DRC
Understanding secondary attack rates is a key knowledge gap in the ongoing clade Ib mpox virus (MPXV) outbreak in the Democratic Republic of the Congo. Here, we report the first cross-sectional serological study to investigate local MPXV clade Ib transmission in South Kivu, DRC. Seropositivity was defined as a detectable titer in a cell lysate-based screening ELISA and confirmation by virus neutralization test. Sera were collected in November and December 2023 (n = 120), and in May 2024 (n = 48) from professional sex workers (PSW) and visitors of 25 bars with reports of mpox cases. We detected serological evidence for MPXV infection in 18% and 17% of these sera, respectively, indicating that PSW played an important role in MPXV clade Ib transmission in this region. Additionally, sera from 108 direct contacts of mpox cases from 34 households were collected between September 2023 and May 2024. Serological evidence for MPXV infection was found in at least one serum sample in 50% of households, including in nine households with seropositive minors, providing evidence for close-contact household transmission. Serological studies are needed to comprehend the extent and severity of the ongoing MPXV outbreak, and may be used to guide targeted vaccination strategies, particularly for high-risk groups.
- 1 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-8
Open AccessSerological evidence of clade Ib Mpox transmission by sex workers and within household in South Kivu, DRC
Understanding secondary attack rates is a key knowledge gap in the ongoing clade Ib mpox virus (MPXV) outbreak in the Democratic Republic of the Congo. Here, we report the first cross-sectional serological study to investigate local MPXV clade Ib transmission in South Kivu, DRC. Seropositivity was defined as a detectable titer in a cell lysate-based screening ELISA and confirmation by virus neutralization test. Sera were collected in November and December 2023 (n = 120), and in May 2024 (n = 48) from professional sex workers (PSW) and visitors of 25 bars with reports of mpox cases. We detected serological evidence for MPXV infection in 18% and 17% of these sera, respectively, indicating that PSW played an important role in MPXV clade Ib transmission in this region. Additionally, sera from 108 direct contacts of mpox cases from 34 households were collected between September 2023 and May 2024. Serological evidence for MPXV infection was found in at least one serum sample in 50% of households, including in nine households with seropositive minors, providing evidence for close-contact household transmission. Serological studies are needed to comprehend the extent and severity of the ongoing MPXV outbreak, and may be used to guide targeted vaccination strategies, particularly for high-risk groups.